Skip Navigation LinksHome > July 1, 2013 - Volume 63 - Issue 3 > Intentions to Use Preexposure Prophylaxis Among Current Phas...
Text sizing:
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e318296df94
Rapid Communication

Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants

Fuchs, Jonathan D. MD, MPH*,†; Sobieszczyk, Magdalena E. MD, MPH; Madenwald, Tamra MA, MPH§; Grove, Doug MS; Karuna, Shelly T. MD§; Andrasik, Michele PhD§; Sherwat, Adam MD; Broder, Gail MHS§; Mayer, Kenneth MD#; Koblin, Beryl PhD**; Hammer, Scott MD; the HVTN 505 Protocol Team

Collapse Box


Abstract: In November 2010, the iPrEx study reported that preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly scheduled follow-up visits from January to March 2011, participants in an ongoing phase 2b vaccine efficacy trial completed an anonymous Web survey about PrEP. Among 376 respondents, 17% reported they were very likely to use PrEP in the next year. Nonwhite participants were more likely to use PrEP. Among those with some level of interest, intent to use PrEP was greatest if the drug were available through the clinical trial or health insurance. Most (91%) believed taking PrEP would not change their willingness to stay in the vaccine trial and few thought it would affect recruitment. As key stakeholders, currently enrolled trial participants can offer vital input about emerging prevention technologies that may affect the design of future HIV vaccine and nonvaccine prevention trials.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.